# Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy

> **NCT04542993** · PHASE2 · TERMINATED · sponsor: **Swedish Medical Center** · enrollment: 45 (actual)

## Conditions studied

- Covid19
- SARS-CoV Infection

## Interventions

- **DIETARY_SUPPLEMENT:** Zinc Picolinate
- **DIETARY_SUPPLEMENT:** Resveratrol
- **DIETARY_SUPPLEMENT:** Zinc Picolinate Placebo
- **DIETARY_SUPPLEMENT:** Resveratrol Placebo

## Key facts

- **NCT ID:** NCT04542993
- **Lead sponsor:** Swedish Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-08
- **Primary completion:** 2021-02-05
- **Final completion:** 2021-02-05
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Difficulty accruing patients
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04542993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04542993, "Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04542993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*